[ad_1]
The remedy was used in Ebola, SARS, and Mars Crown, but the drug was not approved. Because, at that time, not enough activity or effect was observed. And there is still not enough information about it. Therefore, even if used, it should be used with care, experts said. They say the United States Food and Drug Administration (FDA) has cited that the drug is used only in emergencies. The drug is not as effective in the crown as the remediation campaign is.
When asked about the effectiveness of Remediciv in treating Kovid-19, several experts told the Bengali Tribune: “Patients admitted to the hospital who received Remediciv recovered in 11 days, and those who did not receive the medication recovered. recovered in 15 days. ” The only difference between the four days is remediation, nothing more. But if people trust him without understanding it, it will not be good for us, but it will be the opposite. Everyone should understand that no one can wear it if the crown is positive. It should be avoided unnecessarily.
Gilead in the United States has sole ownership of Remdesiv’s production. However, under international trade law, least developed countries such as Bangladesh, recognized by the UN, can revoke these patents. Beximco Pharmaceuticals and SKF Pharmaceuticals, two national companies, have already completed production of the effective antiviral drug Remedacivir against coronavirus. Other preparations that include the manufacturing process include Beacon Pharmaceuticals, Incepta Pharmaceuticals, Healthcare Pharmaceuticals, Square Pharmaceuticals, Popular, and Opsonin. However, this medicine is not currently available on the open market. Only Covid hospitals and dedicated institutes can use this medication for treatment.
The home remedies could hit the market in the middle of this month, the companies said. ‘Remedicivir’ is an antiviral medication. Originally used during Ebola, it is now licensed by the United States Food and Drug Administration (FDA).
“Producers say it is not the only ‘treatment option’,” said Dr. Krishna Kumar, a professor in the Department of Pharmacy at the University of Dhaka. Sitesh Chandra Bachar told the Bengali Tribune: “REMDECV has reduced the length of stay for those who will be admitted to the hospital.” The mechanism of action of this medicine is to stop the growth of the virus in the lungs and blood. This reduces the time you spend in the hospital. And if there is less time in the hospital, the patient benefits. During Ebola it was observed that it could reduce the proliferation of the Ebola virus. It is now approved as part of its pilot program based on that concept. But somewhere it worked, somewhere it didn’t work. That’s why Remediciv’s Covid-19 is said to be not the only tool for treatment, “Sitesh Chandra Bachar said.
Rajdaula Rafi, professor of pharmacy at Jagannath University, told the Bengali Tribune: “The antiviral drugs that have been studied before are still being investigated.” And so far, the remedy has proven somewhat ineffective among those drugs. There is no option without it. The FDA says the remedies can only be used for emergency patients, not for everyone. Emergency patients are those who are hospitalized and have severe respiratory distress. Also, it cannot be given to anyone else. Therefore, we have to be clear about how much we will do in the case of recovery work, in which case it will be done. ”
Rajdaula Rafi said the United States conducted the study on 1,060 patients. His research was not on mortality as in China, but on whether it would reduce hospital stays for those who would recover. Those who have received remediation have been seen to recover in 11 days. And those who did not receive, are recovering in 15 days. And so, since there is no other option available, the USFDA has granted him a “temporary authorization.”
The Chinese study was published in the Lancet Journal, where they say the drug is not effective.
The US FDA USA He has given permission to remedicivir, but from permission it follows that the remedicivar works, commented Professor Dr. Bangabandhu Sheikh Mujib Medical University, chairman of the Department of Pharmacology. Sayedur Rahman. He told the Bengali Tribune that there have been eight studies on remediation, two of which have been rejected, with no benefit in China. But there has been a very large study in the United States, where the benefits have been found. The benefit is that patients can return home in 11 days instead of 15 days. But this single word is not enough. Other than that, the study did not say any other physical harm to the patients, or differences in death rates. They say it has delayed the disease process (remediation) because they have an early recovery, so it can be managed. ”
The “Emergency Use Authorization” is the approval of RemediSvir. Those with an oxygen saturation below 94, those who need to be allowed to increase their oxygen consumption, or those who need ventilation, and those who need ECMO (extracorporeal membrane oxygenation) – these four conditions are recommended for use. in hospitalized patients. But in Bangladesh, more than three to four percent of patients will not go to this condition. But I am afraid that the health care system and the drug marketing system in Bangladesh are such that if this drug enters the marketing system, there is a great possibility of ‘unnecessary need’, “said Dr. Prof. Sayedur Rahman.
Shaheed Suhrawardy Medical College, assistant professor of virology. Zahidur Rahman said: not Antiviral drugs that work directly against any virus other than specific viruses like hepatitis A, hepatitis C and HIV have not been discovered. However, since nothing is close at hand, it can be seen with these medications. There have been some clinical trials in Hategona, and if these trials are on a larger scale, perhaps a conclusion can be drawn. This is because it was originally used for Ebola, and subsequent research has not been very successful with Ebola.
[ad_2]
